DEXCOM INC
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
DXCM$79.92-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 15. Exhibits Financial Statement Schedules
ITEM 15 - EXHIBIT AND FINANCIAL STATEMENT SCHEDULES
(a)The following documents are filed as part of this Annual Report:
- Financial Statements.
The consolidated financial statements listed in Part II, Item 8 of this Annual Report.
- Financial Statement Schedules.
Schedule II – Valuation and Qualifying Accounts.
Financial statement schedules not listed above have been omitted because information required to be set forth therein is not applicable, not required, or the information required by such schedules is shown in the consolidated financial statements or the notes thereto.
- Exhibits.
| ExhibitNumber · Exhibit Description · Incorporated by Reference · ProvidedHerewith | |||||
|---|---|---|---|---|---|
| Form · File No. · Date ofFirst Filing · ExhibitNumber | |||||
| 3.1 | Restated Certificate of Incorporation of DexCom, Inc. | 8-K | 000-51222 | June 10, 2022 | 3.1 |
| 3.2 | Amended and Restated Bylaws of DexCom, Inc. | 10-Q | 000-51222 | October 24, 2024 | 3.1 |
| 4.1 | Form of Specimen Certificate for DexCom, Inc. common stock. | S-1/A | 333-122454 | March 24, 2005 | 4.01 |
| 4.2 | Indenture, dated November 30, 2018, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.75% Convertible Senior Notes due 2023). | 8-K | 000-51222 | December 3, 2018 | 4.1 |
| 4.3 | Indenture, dated May 14, 2020, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.25% Convertible Senior Notes due 2025). | 8-K | 000-51222 | May 15, 2020 | 4.1 |
| 4.4 | Indenture, dated May 5, 2023, between DexCom, Inc. and U.S. Bank Trust Company, National Association (including the form of 0.375% Convertible Senior Notes due 2028). | 8-K | 000-51222 | May 5, 2023 | 4.1 |
| 4.5 | Description of Securities Registered Under Section 12 of the Exchange Act. | 10-K | 000-51222 | February 18, 2025 | 4.5 |
| 10.1* | Offer letter between DexCom, Inc. and Kevin Sayer, dated May 3, 2011. | 10-Q | 000-51222 | August 3, 2011 | 10.28 |
| 10.2 | Sublease between DexCom, Inc. and Entropic Communications, LLC, dated February 1, 2016. | 10-Q | 000-51222 | April 27, 2016 | 10.36 |
| 10.3* | DexCom, Inc. Executive Deferred Compensation Plan. | 8-K | 000-51222 | June 4, 2019 | 10.02 |
| 10.4** | Third Amendment to Office Lease between DexCom, Inc. and John Hancock Life Insurance Company, dated January 9, 2019. | 10-K | 000-51222 | February 13, 2020 | 10.40 |
| 10.5* | Form of Indemnity Agreement between DexCom, Inc. and each of its directors and executive officers. | 10-K | 000-51222 | February 11, 2021 | 10.43 | |
| 10.6* | DexCom, Inc. Incentive Bonus Plan. | 8-K | 000-51222 | March 17, 2021 | 10.1 | |
| 10.7 | Second Amended and Restated Credit Agreement dated October 13, 2021 by and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative Agent. | 10-K | 000-51222 | February 14, 2022 | 10.39 | |
| 10.8 | Office Lease Agreement, dated March 31, 2006, between DexCom, Inc. and Kilroy Realty, L.P., as amended on August 18, 2010 and October 1, 2014. | 10-K | 000-51222 | February 9, 2023 | 10.09 | |
| 10.9** | Fourth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated September 9, 2019, as amended on October 21, 2019, May 25, 2021, and December 23, 2022. | 10-K | 000-51222 | February 9, 2023 | 10.18 | |
| 10.10* | DexCom, Inc. Amended and Restated Severance and Change in Control Plan. | 8-K | 000-51222 | May 19, 2023 | 10.1 | |
| 10.11 | First Amendment to Second Amended and Restated Credit Agreement, dated June 1, 2023 by and between DexCom, Inc. and JPMorgan Chase Bank National Association. | 10-Q | 000-51222 | July 27, 2023 | 10.06 | |
| 10.12** | Amended and Restated Collaboration and License Agreement, dated November 20, 2018, by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences LLC). | 10-K | 000-51222 | February 8, 2024 | 10.14 | |
| 10.13** | Warrant Termination Agreement between DexCom, Inc. and Bank of America, N.A., dated February 13, 2024. | 8-K | 000-51222 | February 15, 2024 | 10.1 | |
| 10.14** | Confidential Settlement and Patent License Agreement, dated December 20, 2024, between Abbott Diabetes Care Inc. and DexCom, Inc. | 10-K | 000-51222 | February 18, 2025 | 10.16 | |
| 10.15* | Amended and Restated 2015 Equity Incentive Plan. | 8-K | 000-51222 | May 9, 2025 | 10.1 | |
| 10.16* | Amended and Restated 2015 Employee Stock Purchase Plan. | 8-K | 000-51222 | May 9, 2025 | 10.2 | |
| 10.17* | Offer Letter, effective January 1, 2026, by and between DexCom, Inc. and Jacob S. Leach. | 8-K | 000-51222 | December 22, 2025 | 10.1 | |
| 10.18* | Form of award agreement under the Amended and Restated 2015 Equity Incentive Plan. | X | ||||
| 10.19* | Form of enrollment agreement under the Amended and Restated 2015 Employee Stock Purchase Plan. | X | ||||
| 19.1* | Insider Trading Policy. | 10-K | 000-51222 | February 18, 2025 | 19.1 | |
| 21.1 | List of Subsidiaries. | X | ||||
| 23.1 | Consent of Independent Registered Public Accounting Firm (Deloitte & Touche LLP). | X | ||||
| 23.2 | Consent of Independent Registered Public Accounting Firm (Ernst & Young LLP). | X | ||||
| 31.1 | Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). | X | ||||
| 31.2 | Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). | X | ||||
| 32.1*** | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b). | X | ||||
| 32.2*** | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b). | X | ||||
| 97.1* | Compensation Recovery Policy. | 10-K | 000-51222 | February 8, 2024 | 97.1 | |
| 101.INS | Inline XBRL Instance Document | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | ||||
| 104 | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101) | X | ||||
| * | Represents a management contract or compensatory plan, contract or arrangement. |
|---|---|
| ** | Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. |
| *** | This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that Dexcom specifically incorporates it by reference. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.